Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
Formule empirique (notation de Hill) :
C42H84ClNO2
Numéro CAS:
Poids moléculaire :
670.57
MDL number:
UNSPSC Code:
12352211
NACRES:
NA.25
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderassay
>99% (TLC)
form
powder
packaging
pkg of 2 × 100 mg (890898P-200mg), pkg of 1 × 25 mg (890898P-25mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand
application(s)
advanced drug delivery
lipid type
cationic lipids
transfection
shipped in
dry ice
storage temp.
−20°C
SMILES string
[H]C(C[N+](C)(C)C)(OCCCCCCCC/C=C\CCCCCCCC)COCCCCCCCC/C=C\CCCCCCCC.[Cl-]
InChI key
LDGWQMRUWMSZIU-LQDDAWAPSA-M
Application
DOTMA is suitable for use as a building block of miRNA delivery system and in the preparation.
Biochem/physiol Actions
DOTMA is a cationic lipid, used as a non-viral vector for gene therapy. It exhibits effective in vitro and in vivo gene transfection. DOTMA induces a positive charge on the liposomes and thus promotes efficient liposome - cell membrane interaction.
Packaging
5 mL Clear Glass Sealed Ampule (890898P-200mg)
5 mL Clear Glass Sealed Ampule (890898P-25mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
Classe de stockage
11 - Combustible Solids
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
The use of cationic microbubbles to improve ultrasound-targeted gene delivery to the ischemic myocardium
Sun L, et al.
Biomaterials, 34(8), 2107-2116 (2013)
Yun Wu et al.
Molecular therapy. Nucleic acids, 2, e84-e84 (2013-04-18)
MicroRNA-29b (miR-29b) expression has been shown to be reduced in non-small-cell lung cancer (NSCLC) tissues. Here, we have identified the oncogene cyclin-dependent protein kinase 6 (CDK6) as a direct target of miR-29b in lung cancer. We hypothesized that in vivo
Jinhong Meng et al.
Scientific reports, 10(1), 1046-1046 (2020-01-25)
P53 mutations are responsible for drug-resistance of tumour cells which impacts on the efficacy of treatment. Alternative tumour suppressor pathways need to be explored to treat p53- deficient tumours. The E3 ubiquitin ligase, ITCH, negatively regulates the tumour suppressor protein
Numéro d'article de commerce international
| Référence | GTIN |
|---|---|
| 890898P-200MG | 04061835188581 |
| 890898P-25MG | 04061835188598 |